The Pharmaceutical companies and chemists in Shimla have begun implementing the revised GST night tariff on medicines, bringing much-needed relief to patients and the poor.
Samajwadi Party chief Akhilesh Yadav on Friday termed Bharatiya Janata Party's foreign policy a "failure", blaming the government for the "suffering" of India's businesses and trade due to the tariffs imposed by the US.
European countries are expected to face the most immediate and severe impact from the new U.S. tariffs on imported branded or patented pharmaceutical products, while India may remain less affected for now, according to a press release by the Global Trade Research Initiative (GTRI).
India's pharmaceutical exports are not expected to face a major impact following the recent announcement of a 100 per cent tariff on branded and patented pharmaceutical products by the US, said Sudarshan Jain, General Secretary of the Indian Pharmaceutical Alliance (IPA).
Americans will be the first to be affected, said Niranjan Hiranandani, Founder and Chairman of the Hiranandani Group on Friday, in response to U.S. President Donald J. Trump's announcement of a 100 per cent tariff on branded and patented pharmaceutical products.
Chairperson of the topmost Pharmaceutical company, Pharmexcil, which earns 40 - 50 per cent of its total revenues from the American market also said, "Generic drugs are not impacted".
The Indian pharmaceutical sector supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicines in the UK. According to a government release, drug and pharmaceutical exports increased by 6.94 per cent from USD 2.35
In a post on Truth Social, President Trump wrote, "Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. 'IS BUILDING' will be defined as 'breaking
Speaking at the India-SICA Foreign Minister's Meeting in New York, Jaishankar expressed optimism about the growing interest of Indian companies to invest in SICA economies, especially in agriculture, renewable energy, pharmaceuticals, and information technology sectors.
Manesar (Haryana) [India], September 25: Camfil has added a new production line for HEPA and ULPA filters at its Manesar plant, increasing supply capacity for hospitals, pharmaceutical cleanrooms, biotechnology labs, and other high-containment facilities.
The West Asian nation of Jordan is keen to deepen economic ties with India by attracting investments in key sectors such as information technology (IT), artificial intelligence (AI), pharmaceuticals, renewable energy, and green energy, said Youssef Abdelghani, Jordan's Ambassador to India.
Mumbai (Maharashtra) [India], September 24: HVAX Technologies Limited (NSE -HVAX), a turnkey pharmaceutical project integrator, has announced key business highlights that reinforce its strong growth trajectory.